RNA

Business Context and Reporting Period

Atrium Therapeutics, Inc. (Nasdaq: RNA) is a clinical-stage biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies. This Form 10-Q covers the quarterly period ended June 30, 2026. The Company became an independent, publicly traded entity on February 26, 2026, following a spin-off from Avidity Biosciences, Inc. (now a subsidiary of Novartis AG). Prior to the spin-off, financial results were derived from the Former Parent's consolidated statements.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Collaboration revenue increased by $17.2 million for the six months ended June 30, 2026, compared to the same period in 2025. This increase was primarily driven by the recognition of a $15.0 million milestone payment under the Bristol Myers Squibb (BMS) Collaboration Agreement.
• Operating Expenses: Total operating expenses increased significantly by $36.8 million for the six-month period compared to 2025.
  • R&D Expenses: Increased by $11.8 million, driven by higher contract manufacturing costs and internal personnel costs, including executive transition bonuses and accelerated stock-based compensation.
  • G&A Expenses: Increased by $25.0 million, primarily due to higher personnel costs and external professional services required to support operations as an independent public company.
• Liquidity: As of June 30, 2026, the Company held $263.9 million in cash and short-term investments. This represents a substantial increase from the prior period, where the Company had no independent cash balance as it was managed centrally by the Former Parent.
• Stock-Based Compensation: Total stock-based compensation expense was $13.1 million for the six months ended June 30, 2026, compared to $2.9 million in the prior year period, largely due to accelerated vesting associated with the spin-off.

Guidance, Outlook, and Risks

• Outlook: Management believes existing cash, cash equivalents, and short-term investments are sufficient to fund operations for at least 12 months from the filing date. The Company expects to continue incurring operating losses as it advances clinical development.
• Product Pipeline:
  • ATR 1072: Lead candidate for PRKAG2 syndrome. IND cleared by the FDA; Phase 1/2 clinical trial (Corventis) is underway with first participant enrollment expected by end of 2026. Initial data anticipated in H2 2027.
  • ATR 1086: Lead candidate for PLN cardiomyopathy. IND filing expected in 2027.
• Subsequent Event: In August 2026, the Company achieved a milestone under the BMS Collaboration Agreement, entitling it to a $15.0 million payment.
• Risks:
  • Capital Requirements: The Company will require substantial additional financing to achieve its goals. Failure to obtain capital could force delays or termination of development programs.
  • Spin-Off Transition: Historical financial data may not reflect future standalone costs. The Company faces increased costs for corporate functions, IT, and compliance as an independent entity.
  • Intellectual Property: Reliance on the Avidity License Agreement for key platform IP. Avidity (Novartis) retains rights to certain IP and may compete in the cardiac space.
  • Collaboration Risks: Revenue depends on milestones from BMS and Eli Lilly. These partners may terminate agreements for convenience.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $263.9 million liquidity position against the projected burn rate for the next 12-24 months, considering the high cost of clinical trials.
• Revenue Recognition: Confirm the timing and certainty of future milestone payments from BMS and Lilly, noting that variable consideration is constrained until milestones are achieved.
• Expense Structure: Assess the sustainability of the increased G&A and R&D expenses post-spin-off compared to the allocated costs under the Former Parent.
• IP Dependencies: Review the terms of the Avidity License Agreement regarding the assignment of platform IP and potential competition from Novartis/Avidity.
• Clinical Milestones: Monitor the enrollment progress of the ATR 1072 Corventis trial and the timeline for the ATR 1086 IND filing.